At the 2026 European Congress on Obesity (ECO) in Istanbul, researchers presented a small observational study assessing fasting peptide YY (PYY), ghrelin, and glucose-dependent insulinotropic polypeptide (GIP) levels in people living with type 1 diabetes (T1D) and obesity. The study aimed to explore gut hormone signaling differences in this population.
The study included 20 participants with T1D and obesity, compared to 20 matched controls without diabetes. Fasting levels of PYY, ghrelin, and GIP were measured. Results showed that participants with T1D and obesity had significantly lower fasting PYY levels and higher fasting ghrelin levels compared to controls. GIP levels did not differ significantly between groups.
These findings suggest that gut hormone signaling may be altered in individuals with T1D and obesity, potentially contributing to appetite dysregulation and metabolic challenges. The researchers noted that further studies are needed to confirm these results and explore therapeutic implications.
The study was presented at ECO 2026, which took place from May 12-15, 2026, in Istanbul, Turkey. The research was conducted by a team from the University of Copenhagen and Rigshospitalet in Denmark.
